Philogen Past Earnings Performance
Past criteria checks 0/6
Philogen's earnings have been declining at an average annual rate of -30.1%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 11.1% per year.
Key information
-30.1%
Earnings growth rate
-26.9%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | 11.1% |
| Return on equity | -5.5% |
| Net Margin | -20.0% |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Philogen makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 27 | -5 | 11 | 0 |
| 30 Sep 22 | 25 | -5 | 10 | 0 |
| 30 Jun 22 | 23 | -5 | 10 | 0 |
| 31 Mar 22 | 14 | -10 | 9 | 0 |
| 31 Dec 21 | 5 | -16 | 9 | 0 |
| 30 Sep 21 | 6 | -14 | 8 | 0 |
| 30 Jun 21 | 6 | -14 | 8 | 0 |
| 31 Mar 21 | 6 | -13 | 8 | 0 |
| 31 Dec 20 | 6 | -13 | 7 | 0 |
| 30 Sep 20 | 8 | -11 | 8 | 0 |
| 31 Dec 19 | 15 | 1 | 7 | 0 |
| 31 Dec 18 | 16 | 4 | 6 | 0 |
| 31 Dec 17 | 14 | 3 | 5 | 0 |
Quality Earnings: PHILM is currently unprofitable.
Growing Profit Margin: PHILM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PHILM is unprofitable, and losses have increased over the past 5 years at a rate of 30.1% per year.
Accelerating Growth: Unable to compare PHILM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PHILM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: PHILM has a negative Return on Equity (-5.49%), as it is currently unprofitable.